KR20060086396A - 바이사이클릭 피라졸일 및 이미다졸일 화합물, 및 이의용도 - Google Patents
바이사이클릭 피라졸일 및 이미다졸일 화합물, 및 이의용도 Download PDFInfo
- Publication number
- KR20060086396A KR20060086396A KR1020067008880A KR20067008880A KR20060086396A KR 20060086396 A KR20060086396 A KR 20060086396A KR 1020067008880 A KR1020067008880 A KR 1020067008880A KR 20067008880 A KR20067008880 A KR 20067008880A KR 20060086396 A KR20060086396 A KR 20060086396A
- Authority
- KR
- South Korea
- Prior art keywords
- chlorophenyl
- compound
- trifluoroethyl
- alkyl
- triaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OOLCZEWBAIAKJX-UHFFFAOYSA-N CC(CN(CCCl)C(c(c(O)c1-c(cc2)ccc2Cl)n[n]1-c(cccc1)c1Cl)=O)(F)F Chemical compound CC(CN(CCCl)C(c(c(O)c1-c(cc2)ccc2Cl)n[n]1-c(cccc1)c1Cl)=O)(F)F OOLCZEWBAIAKJX-UHFFFAOYSA-N 0.000 description 1
- YERYKYZTWPSPMW-UHFFFAOYSA-N CC(Oc1c(-c(cc2)ccc2Cl)[n](-c(cccc2)c2Cl)nc1C(O)=O)=O Chemical compound CC(Oc1c(-c(cc2)ccc2Cl)[n](-c(cccc2)c2Cl)nc1C(O)=O)=O YERYKYZTWPSPMW-UHFFFAOYSA-N 0.000 description 1
- 0 CCC(CN(CCOc1c(-c(cc2)ccc2Cl)[n](-c2c(*)cccc2)nc11)C1=O)(F)F Chemical compound CCC(CN(CCOc1c(-c(cc2)ccc2Cl)[n](-c2c(*)cccc2)nc11)C1=O)(F)F 0.000 description 1
- OOVJAFVWXRIMFQ-UHFFFAOYSA-N CCOC(c(c(OCC=O)c1-c(cc2)ccc2Cl)n[n]1-c1ccccc1Cl)=O Chemical compound CCOC(c(c(OCC=O)c1-c(cc2)ccc2Cl)n[n]1-c1ccccc1Cl)=O OOVJAFVWXRIMFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51828003P | 2003-11-07 | 2003-11-07 | |
| US60/518,280 | 2003-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060086396A true KR20060086396A (ko) | 2006-07-31 |
Family
ID=34572986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067008880A Abandoned KR20060086396A (ko) | 2003-11-07 | 2004-10-25 | 바이사이클릭 피라졸일 및 이미다졸일 화합물, 및 이의용도 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7151097B2 (https=) |
| EP (1) | EP1682554A1 (https=) |
| JP (2) | JP4056549B2 (https=) |
| KR (1) | KR20060086396A (https=) |
| CN (1) | CN1886407A (https=) |
| AP (1) | AP2006003601A0 (https=) |
| AR (1) | AR046831A1 (https=) |
| AU (1) | AU2004286909A1 (https=) |
| BR (1) | BRPI0416299A (https=) |
| CA (1) | CA2544752A1 (https=) |
| CR (1) | CR8387A (https=) |
| DO (1) | DOP2004001024A (https=) |
| EA (1) | EA009742B1 (https=) |
| EC (1) | ECSP066549A (https=) |
| GT (1) | GT200400226A (https=) |
| HR (1) | HRP20060166A2 (https=) |
| IL (1) | IL175283A0 (https=) |
| IS (1) | IS8426A (https=) |
| MA (1) | MA28151A1 (https=) |
| MX (1) | MXPA06005023A (https=) |
| NL (1) | NL1027434C2 (https=) |
| NO (1) | NO20062618L (https=) |
| OA (1) | OA13280A (https=) |
| PA (1) | PA8616801A1 (https=) |
| PE (1) | PE20050576A1 (https=) |
| TN (1) | TNSN06129A1 (https=) |
| TW (2) | TWI280245B (https=) |
| WO (1) | WO2005044822A1 (https=) |
| ZA (1) | ZA200603594B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11191814B2 (en) | 2018-09-04 | 2021-12-07 | Paw Power, Inc. | Pet food formulation with cannabinoids |
| KR20220044738A (ko) * | 2019-08-09 | 2022-04-11 | 니혼노야쿠가부시키가이샤 | 옥사제피논 유도체, 이 유도체를 함유하는 농원예용 살충제, 및 그의 사용방법 |
| US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| CN101027285A (zh) * | 2004-09-27 | 2007-08-29 | 辉瑞产品公司 | 制备双环吡唑基化合物的方法 |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EP1874779A1 (en) * | 2005-04-20 | 2008-01-09 | Pfizer Products Inc. | Acylaminobicyclic heteromatic compounds as cannabinoid receptor ligands |
| EP1890767A2 (en) * | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| US8378096B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| EP1951678A1 (en) * | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
| WO2007060525A2 (en) | 2005-11-28 | 2007-05-31 | Pfizer Products Inc. | Process for preparing bicyclic pyrazolyl and imidazolyl compounds |
| WO2007096763A2 (en) * | 2006-02-23 | 2007-08-30 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
| WO2008048648A2 (en) * | 2006-10-17 | 2008-04-24 | Acadia Pharmaceuticals Inc. | Cb1-modulating compounds and their use |
| CN101583593A (zh) | 2006-11-13 | 2009-11-18 | 辉瑞产品公司 | 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途 |
| US20090062253A1 (en) * | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| KR101280786B1 (ko) * | 2008-08-06 | 2013-07-05 | 화이자 리미티드 | 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물 |
| US9549006B2 (en) * | 2013-07-31 | 2017-01-17 | Cisco Technology, Inc. | Self-adaptive sample period for content sharing in communication sessions |
| ES2799582T3 (es) * | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| CA2457922A1 (en) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
| MXPA04002249A (es) | 2001-09-24 | 2004-06-29 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad. |
| GB0207249D0 (en) | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US20040077650A1 (en) | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| WO2004098520A2 (en) | 2003-05-01 | 2004-11-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MXPA05011922A (es) | 2003-05-07 | 2006-02-17 | Pfizer Prod Inc | Ligandos del receptor de cannabinoides y sus usos. |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US20050026983A1 (en) | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| CN101027285A (zh) * | 2004-09-27 | 2007-08-29 | 辉瑞产品公司 | 制备双环吡唑基化合物的方法 |
-
2004
- 2004-10-22 US US10/971,599 patent/US7151097B2/en not_active Expired - Fee Related
- 2004-10-25 CA CA002544752A patent/CA2544752A1/en not_active Abandoned
- 2004-10-25 WO PCT/IB2004/003522 patent/WO2005044822A1/en not_active Ceased
- 2004-10-25 EP EP04769741A patent/EP1682554A1/en not_active Withdrawn
- 2004-10-25 KR KR1020067008880A patent/KR20060086396A/ko not_active Abandoned
- 2004-10-25 JP JP2006538974A patent/JP4056549B2/ja not_active Expired - Fee Related
- 2004-10-25 HR HR20060166A patent/HRP20060166A2/xx not_active Application Discontinuation
- 2004-10-25 EA EA200600647A patent/EA009742B1/ru not_active IP Right Cessation
- 2004-10-25 AP AP2006003601A patent/AP2006003601A0/xx unknown
- 2004-10-25 OA OA1200600145A patent/OA13280A/en unknown
- 2004-10-25 CN CNA2004800352698A patent/CN1886407A/zh active Pending
- 2004-10-25 BR BRPI0416299-4A patent/BRPI0416299A/pt not_active IP Right Cessation
- 2004-10-25 AU AU2004286909A patent/AU2004286909A1/en not_active Abandoned
- 2004-10-25 MX MXPA06005023A patent/MXPA06005023A/es not_active Application Discontinuation
- 2004-11-02 TW TW093133372A patent/TWI280245B/zh not_active IP Right Cessation
- 2004-11-02 TW TW095142275A patent/TW200716135A/zh unknown
- 2004-11-02 PA PA20048616801A patent/PA8616801A1/es unknown
- 2004-11-03 DO DO2004001024A patent/DOP2004001024A/es unknown
- 2004-11-04 PE PE2004001074A patent/PE20050576A1/es not_active Application Discontinuation
- 2004-11-04 GT GT200400226A patent/GT200400226A/es unknown
- 2004-11-05 AR ARP040104075A patent/AR046831A1/es not_active Application Discontinuation
- 2004-11-05 NL NL1027434A patent/NL1027434C2/nl not_active IP Right Cessation
-
2006
- 2006-04-21 IS IS8426A patent/IS8426A/is unknown
- 2006-04-27 IL IL175283A patent/IL175283A0/en unknown
- 2006-05-05 ZA ZA200603594A patent/ZA200603594B/en unknown
- 2006-05-05 TN TNP2006000129A patent/TNSN06129A1/fr unknown
- 2006-05-05 CR CR8387A patent/CR8387A/es not_active Application Discontinuation
- 2006-05-05 MA MA29005A patent/MA28151A1/fr unknown
- 2006-05-05 EC EC2006006549A patent/ECSP066549A/es unknown
- 2006-06-07 NO NO20062618A patent/NO20062618L/no not_active Application Discontinuation
- 2006-09-07 US US11/470,695 patent/US20070027133A1/en not_active Abandoned
-
2007
- 2007-07-12 JP JP2007183117A patent/JP2007302685A/ja not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11191814B2 (en) | 2018-09-04 | 2021-12-07 | Paw Power, Inc. | Pet food formulation with cannabinoids |
| US11504416B2 (en) | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
| KR20220044738A (ko) * | 2019-08-09 | 2022-04-11 | 니혼노야쿠가부시키가이샤 | 옥사제피논 유도체, 이 유도체를 함유하는 농원예용 살충제, 및 그의 사용방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060086396A (ko) | 바이사이클릭 피라졸일 및 이미다졸일 화합물, 및 이의용도 | |
| JP4018736B2 (ja) | カンナビノイド受容体リガンドとしてのピラゾロ［１，５−ａ］［１，３，５］トリアジン誘導体 | |
| US7354929B2 (en) | Cannabinoid receptor ligands and uses thereof | |
| US7145012B2 (en) | Cannabinoid receptor ligands and uses thereof | |
| CA2515596C (en) | Cannabinoid receptor ligands and uses thereof | |
| JP3917647B2 (ja) | カンナビノイド受容体リガンド及びその使用 | |
| KR20060006048A (ko) | 카나비노이드 수용체 리간드 및 그의 용도 | |
| WO2005061507A1 (en) | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof | |
| WO2005049615A1 (en) | Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20060508 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070430 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20071024 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20080401 |
|
| NORF | Unpaid initial registration fee | ||
| PC1904 | Unpaid initial registration fee |